This months Living Beyond Dementia™ blog (yes, only one again as I am too busy living beyond dementia), is on the following study (Abstract and Summary only included – follow the link to the full study),
- 1 Mary S. Easton Center for Alzheimer’s Disease Research, Department of Neurology, University of California, Los Angeles, CA 90095;
- 2 Buck Institute for Research on Aging, Novato, CA 94945.
•A novel, comprehensive, and personalized therapeutic system is described that is based on the underlying pathogenesis of Alzheimer’s disease. The basic tenets for the development of this system are also described.
•Of the first 10 patients who utilized this program, including patients with memory loss associated with Alzheimer’s disease (AD), amnestic mild cognitive impairment (aMCI), or subjective cognitive impairment (SCI), nine showed subjective or objective improvement.
•One potentially important outcome is that all six of the patients whose cognitive decline had a major impact on job performance were able to return to work or continue working without difficulty.
•These anecdotal results suggest the need for a controlled clinical trial of the therapeutic program.
Blog author’s comment:
What I believe this study indicates is that further studies are warranted to support this anecdotal evidence, and it is excellent to report that is in progress. Whilst this is a very small sample, in view of the fact that until now no cases of reversal have ever been documented by an expert it adds weight to the findings.
People with dementia deserve better, and for these types of studies to be expanded, and I have heard very recently (via a colleague) that Dr Bredesen and his new CEO Thom Mount report a 90% success in 112 patients and that there are soon to be new trials at Oxford and the Cleveland Clinic.